Cardiovascular, Pulmonary, and Integrative Functional Phenotypes in COVID-19 Survivors – Effect of Fenofibrate

Overview

The International multicenter FEnofibRate as a Metabolic INtervention for COVID-19 (FERMIN) trial is being executed. The trial is testing a short intervention (10 days of fenofibrate therapy) on 30-day outcomes in COVID-19. The overarching goal of this sub-study is to explore the impact of fenofibrate on key longer term phenotypes of vascular, cardiac and pulmonary health, integrated cardiopulmonary function, persistent/chronic symptoms and quality of life.

Full Title of Study: “Cardiovascular, Pulmonary, and Integrative Functional Phenotypes in COVID-19 – Effect of Fenofibrate”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 31, 2023

Detailed Description

The International multicenter FEnofibRate as a Metabolic INtervention for COVID-19 (FERMIN) trial is being executed. The aim of this trial is to assess the impact of fenofibrate (administered for 10 days) to improve clinical outcomes in patients with COVID-19, assessed at 30 days. However, given the accumulating evidence of chronic / long term sequelae of COVID-19, it is important to assess the long-term impact of this intervention in this patient population. The overarching goal of this substudy is to assess the impact of fenofibrate on key intermediate phenotypes of vascular, cardiac and pulmonary health. We also aim to address the impact of fenofibrate therapy (administered during the acute COVID-19 episode as part of the parent FERMIN trial) on long-term integrated cardiopulmonary function, persistent/chronic symptoms and quality of life. We will accomplish this via enrollment of previous FERMIN participants from the University of Pennsylvania, in an phenotyping study designed to assess vascular, cardiac and pulmonary status several months after the index episode of COVID-19. We will perform these assessments ~6 months after initial randomization, among 40 FERMIN trial participants enrolled at the University of Pennsylvania.

Interventions

  • Drug: Fenofibrate
    • 145 mg/d of Tricor (administered as part of the parent FERMIN trial) for 10 days, or renal corrected dose equivalent (depending on renal function)
  • Drug: Placebo
    • Matching placebo (once/day) for 10 days

Arms, Groups and Cohorts

  • Fenofibrate recipients
    • Approximately 20 subjects who were randomized to the Fenofibrate arm in the FERMIN trial. This drug was administered for 10 days post-randomization.
  • Placebo recipients
    • Approximately 20 subjects who were randomized to the placebo arm in the FERMIN trial. This drug was administered for 10 days post-randomization.

Clinical Trial Outcome Measures

Primary Measures

  • Flow Mediated dilation of the brachial artery
    • Time Frame: ~6 months
    • Flow Mediated dilation of the brachial artery measured with ultrasound. This is a metric of endothelial function
  • Arterial wave reflection magnitude
    • Time Frame: ~6 months
    • Arterial wave reflection magnitude measured with high fidelity arterial tonometry and wave separation analysis
  • Large Artery Stiffness
    • Time Frame: ~6 months
    • Carotid-femoral pulse wave velocity measured with arterial tonometry
  • Myocardial function
    • Time Frame: ~6 months
    • Peak longitudinal strain assessed with echocardiography
  • Diffusion capacity of lungs for carbon monoxide (DLCO)
    • Time Frame: ~6 months
    • Diffusion capacity of lungs for carbon monoxide (DLCO) measured during pulmonary function testing
  • Aerobic capacity
    • Time Frame: ~6 months
    • Measured as Peak oxygen consumption during a cardiopulmonary exercise test
  • Quality of life
    • Time Frame: ~6 months
    • Quality of life measured with the Kansas City Cardiomyopathy questionnaire

Participating in This Clinical Trial

Inclusion Criteria

• Having been eligible, enrolled and randomized in the parent FERMIN trial, completing all study procedures up to the 30-day time point (as specified in the parent protocol). Exclusion Criteria

  • Prisoners/incarcerated individuals; – Pregnancy (potentially eligible patients of reproductive age will undergo a pregnancy test). This exclusion is due to the fact that pregnancy may confound the various cardiopulmonary phenotypes assessed in this study – Inability to provide informed consent. – History of cardiovascular disease (defined as heart failure, myocardial infarction, coronary revascularization, serious arrhythmia, stroke, or peripheral artery disease), glomerular disease or polycystic kidney disease prior to the index COVID-19 episode. – Estimated glomerular filtration rate <30 mL/min/1.73m2 prior to the index COVID-19 episode.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Pennsylvania
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Julio A Chirinos, MD, PhD, 215-200-7779, julio.chirinos@pennmedicine.upenn.edu

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.